✦ LIBER ✦

Farnesyl transferase inhibitor (lonafarnib) in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia: a phase II study

✍ Scribed by Christophe Ravoet; Philippe Mineur; Valérie Robin; Louisette Debusscher; André Bosly; Marc André; Hakim El Housni; Anne Soree; Dominique Bron; Philippe Martiat

Publisher: Springer
Year: 2008
Tongue: English
Weight: 101 KB
Volume: 87
Category: Article
ISSN: 0939-5555
DOI: 10.1007/s00277-008-0536-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pilot study of lonafarnib, a farnesyl tr

Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy

✍ Gautam Borthakur; Hagop Kantarjian; George Daley; Moshe Talpaz; Susan O'Brien; G 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 105 KB 👁 2 views

A Phase 2 study of combination therapy w

A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemia

✍ Mikkael A. Sekeres; Jaroslaw P. Maciejewski; Harry P. Erba; Manuel Afable; Ricki 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 164 KB 👁 2 views

Allogeneic stem cell transplantation aft

Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia

✍ N. Kröger; M. Bornhäuser; G. Ehninger; R. Schwerdtfeger; H. Biersack; H. G. Saye 📂 Article 📅 2003 🏛 Springer 🌐 English ⚖ 201 KB

A phase I safety, pharmacological, and b

A phase I safety, pharmacological, and biological study of the farnesyl protein transferase inhibitor, lonafarnib (SCH 663366), in combination with cisplatin and gemcitabine in patients with advanced solid tumors

✍ Laura Q. M. Chow; S. Gail Eckhardt; Cindy L. O’Bryant; Mary Kay Schultz; Mark Mo 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 697 KB

Phase II study of the histone deacetylas

Phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in patients with low or intermediate-1 risk myelodysplastic syndrome

✍ Sophie Dimicoli; Elias Jabbour; Gautam Borthakur; Tapan Kadia; Zeev Estrov; Hui 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 850 KB

Results of a phase 2 study of valproic a

Results of a phase 2 study of valproic acid alone or in combination with all-transretinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia

✍ Andrea Kuendgen; Sabine Knipp; Frank Fox; Corinna Strupp; Barbara Hildebrandt; C 📂 Article 📅 2005 🏛 Springer 🌐 English ⚖ 97 KB